Peter Pickkers is an internist-intensivist and professor of Experimental Intensive Care Medicine. His research focuses on modulation of the innate immune response in translational models and patients, sepsis and specific organ dysfunction, among which the kidney. At this moment he supervises 16 PhD-students, 3 post-docs, 3 research nurses and 1 technician. He has co-authored >300 articles and 25 book chapters and is a member of several steering committees of current sepsis trials. He is the principle investigator of the STOP-AKI trial that investigates the effects of recombinant human alkaline phosphatase in patients with sepsis-induced acute kidney injury. In 60 sites worldwide 290 patients will be enrolled.